143 related articles for article (PubMed ID: 37034211)
1. Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer.
Wang Y; Xun Z; Yang X; Wang Y; Wang S; Xue J; Zhang N; Yang X; Lu Z; Zhou J; Zhou K; Sang X; Zhao H
Am J Cancer Res; 2023; 13(3):1026-1037. PubMed ID: 37034211
[TBL] [Abstract][Full Text] [Related]
2. Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC.
Wang Y; Zhang N; Xue J; Zhu C; Wang Y; Zhang L; Yang X; Wang H; Wang S; Chao J; Yang X; Zhao H
Front Immunol; 2023; 14():1084843. PubMed ID: 36733485
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial.
Lai Z; He M; Bu X; Xu Y; Huang Y; Wen D; Li Q; Xu L; Zhang Y; Wei W; Chen M; Kan A; Shi M
Eur J Cancer; 2022 Oct; 174():68-77. PubMed ID: 35981413
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.
Wang Y; Yang X; Wang Y; Xue J; Zhang N; Yang X; Cong N; Zhang J; Zhu C; Zhang L; Hou X; Zhao H
Cancer Immunol Immunother; 2023 Jul; 72(7):2197-2204. PubMed ID: 36856834
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer.
Zhu C; Xue J; Wang Y; Wang S; Zhang N; Wang Y; Zhang L; Yang X; Long J; Yang X; Sang X; Zhao H
Front Immunol; 2023; 14():1109292. PubMed ID: 36742297
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
Front Immunol; 2022; 13():801909. PubMed ID: 35309350
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract][Full Text] [Related]
8. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
9. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.
Dong X; Zhang Z; Zhang Q; Chen L; Cao G; Liu C; Song T; Lu W; Zhang W
J Cancer Res Clin Oncol; 2023 May; 149(5):1917-1927. PubMed ID: 35802197
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy
He MK; Liang RB; Zhao Y; Xu YJ; Chen HW; Zhou YM; Lai ZC; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Li QJ; Shi M
Ther Adv Med Oncol; 2021; 13():17588359211002720. PubMed ID: 33854567
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study.
Zhang Q; Liu X; Wei S; Zhang L; Tian Y; Gao Z; Jin M; Yan S
Front Oncol; 2021; 11():751391. PubMed ID: 34900698
[TBL] [Abstract][Full Text] [Related]
12. A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer.
Zhou M; Jin Y; Zhu S; Xu C; Li L; Liu B; Shen J
Clin Transl Immunology; 2024; 13(1):e1483. PubMed ID: 38223257
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma.
Xiang YJ; Wang K; Yu HM; Li XW; Cheng YQ; Wang WJ; Feng JK; Bo MH; Qin YY; Zheng YT; Shan YF; Zhou LP; Zhai J; Cheng SQ
Hepatol Res; 2022 Aug; 52(8):721-729. PubMed ID: 35536197
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.
Mo DC; Luo PH; Huang SX; Wang HL; Huang JF
Int Immunopharmacol; 2021 Feb; 91():107281. PubMed ID: 33338862
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma.
Lin J; Yang X; Long J; Zhao S; Mao J; Wang D; Bai Y; Bian J; Zhang L; Yang X; Wang A; Xie F; Shi W; Yang H; Pan J; Hu K; Guan M; Zhao L; Huo L; Mao Y; Sang X; Wang K; Zhao H
Hepatobiliary Surg Nutr; 2020 Aug; 9(4):414-424. PubMed ID: 32832493
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC).
He M; Huang Y; Du Z; Lai Z; Ouyang H; Shen J; Wen D; Li Q; Zhang Y; Wei W; Chen M; Xu L; Kan A; Shi M
Clin Cancer Res; 2023 Dec; 29(24):5104-5115. PubMed ID: 37819944
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.
Zhao L; Chang N; Shi L; Li F; Meng F; Xie X; Xu Z; Wang F
Heliyon; 2022 Jun; 8(6):e09538. PubMed ID: 35706954
[TBL] [Abstract][Full Text] [Related]
19. Toripalimab in advanced biliary tract cancer.
Li W; Wang Y; Yu Y; Li Q; Wang Y; Zhang C; Xu X; Guo X; Dong Y; Cui Y; Hao Q; Huang L; Liu H; Liu T
Innovation (Camb); 2022 Jul; 3(4):100255. PubMed ID: 35615603
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma.
Wang Y; Yang X; Wang D; Yang X; Wang Y; Long J; Zhou J; Lu Z; Mao Y; Sang X; Guan M; Zhao H
Front Oncol; 2022; 12():785535. PubMed ID: 35311147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]